A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model

PURPOSE: Currently >50% of high-risk neuroblastoma (NB) patients, despite intensive therapy and initial partial or complete response, develop recurrent NB due to the persistence of minimal residual disease (MRD) that is resistant to conventional antitumor drugs. Indeed, their low therapeutic inde...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Drug Des Devel Ther
Main Authors: Orienti, Isabella, Nguyen, Ferro, Guan, Peng, Kolla, Venkatadri, Calonghi, Natalia, Farruggia, Giovanna, Chorny, Michael, Brodeur, Garrett M
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6930389/
https://ncbi.nlm.nih.gov/pubmed/31908416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S221909
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados